Search Results

Verrica Pharmaceuticals Inc. announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum in Japan.

Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.